Is Sangamo Therapeutics Pointing Toward Success?Seeking AlphaSangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. The … Continue reading
NewsweekNew Natural Selection: How Scientists Are Altering DNA to …NewsweekScientists are altering our genetic code and engineering new forms of material that improve nature, from flowers that can detect bombs to bacteria that secretes …and mo… Continue reading
Phys.OrgHow soil dwelling bacteria adapt to richer or poorer conditionsPhys.OrgThe breakthrough offers multiple new applications, according to the team of John Innes Centre scientists behind the discovery: for the study of human pathogens, for syntheti… Continue reading
Phys.OrgHow soil dwelling bacteria adapt to richer or poorer conditionsPhys.OrgThe breakthrough offers multiple new applications, according to the team of John Innes Centre scientists behind the discovery: for the study of human pathogens, for syntheti… Continue reading
AML: Cellectis testing allogenic CAR-T cell therapyEuropean BiotechnologyWhile Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allo… Continue reading
Nature.com |
Macrophages steal the show
Nature.com The past decade has seen remarkable advances in tumour immunology due to extensive research on inhibition of programmed cell death protein 1 (PD1) — which is expressed on T cells — and its ligand PDL1, which is expressed on tumour cells. However … |
Proactive Investors UK |
ReNeuron Group upbeat as it progresses on all stem cell fronts
Proactive Investors UK Stem cell therapy specialist Reneuron PLC (LON:RENE) is making good progress on all of its clinical trial candidates and also in the lab, chief executive Olav Hellebo said today. “Our therapeutic development programmes have continued to progress well … |
Proactive Investors UK |
ReNeuron Group upbeat as it progresses on all stem cell fronts
Proactive Investors UK Stem cell therapy specialist Reneuron PLC (LON:RENE) is making good progress on all of its clinical trial candidates and also in the lab, chief executive Olav Hellebo said today. “Our therapeutic development programmes have continued to progress well … |